Author

T. H. Burgess

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Ganesan· 3 shared E. D. Laing· 3 shared M. P. Simons· 3 shared B. K. Agan· 2 shared C. C. Broder· 2 shared C. D. Weiss· 2 shared C. J. Colombo· 2 shared D. A. Lindholm· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Ganesan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivJul 5, 2022

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

W. Wang, S. Lusvarghi, R. Subramanian…·C. D. Weiss

The paper compares antibody responses to different SARS-CoV-2 variants after vaccination and infection, finding that post-vaccination Omicron infection induces broader immunity than triple vaccination alone.

DOI 10.1016/j.chom.2022.10.012

humanproteomics

𝕏 PostBluesky

MicrobiologybioRxivDec 22, 2021

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

S. Lusvarghi, S. D. Pollett, S. N. Neerukonda…·C. D. Weiss

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

DOI 10.1126/scitranslmed.abn8543

humanexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintAug 11, 2021

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection

Z. Lu, E. D. Laing, J. Pena-Damata…·A. M. Malloy

This study examines SARS-CoV-2-specific T cell responses 12-months post-infection, finding durable responses with higher frequencies in those with severe acute illness.

DOI 10.1101/2021.08.11.455984

humanflow cytometry

𝕏 PostBluesky